Development and dissolution studies of bisphosphonate (clodronate)-containing hydroxyapatite–polylactic acid biocomposites for slow drug delivery

Macha, IJ; Cazalbou, S; Shimmon, R; Ben-Nissan, B; Milthorpe, B

Development and dissolution studies of bisphosphonate (clodronate)-containing hydroxyapatite–polylactic acid biocomposites for slow drug delivery

Macha, IJ

Cazalbou, S Shimmon, R

Ben-Nissan, B Milthorpe, B

Permalink

Publication Type:: Journal Article
Citation:: Journal of Tissue Engineering and Regenerative Medicine, 2017, 11 (6), pp. 1723 - 1731
Issue Date:: 2017-06-01

Closed Access

	Filename	Description	Size
	Macha_et_al-2015-Journal_of_Tissue_Engineering_and_Regenerative_Medicine.pdf	Published Version	648.51 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Macha, IJ https://orcid.org/0000-0002-7517-4537	en_US
dc.contributor.author	Cazalbou, S	en_US
dc.contributor.author	Shimmon, R https://orcid.org/0000-0002-8763-991X	en_US
dc.contributor.author	Ben-Nissan, B	en_US
dc.contributor.author	Milthorpe, B https://orcid.org/0000-0002-0867-9586	en_US
dc.date.available	2015-06-12	en_US
dc.date.issued	2017-06-01	en_US
dc.identifier.citation	Journal of Tissue Engineering and Regenerative Medicine, 2017, 11 (6), pp. 1723 - 1731	en_US
dc.identifier.issn	1932-6254	en_US
dc.identifier.uri	http://hdl.handle.net/10453/95771
dc.description.abstract	Copyright © 2015 John Wiley & Sons, Ltd. An increase in clinical demand on the controlled release of bisphosphonates (BPs) due to complications associated with systemic administration, has been the current driving force on the development of BP drug-release systems. Bisphosphonates have the ability to bind to divalent metal ions, such as Ca2+, in bone mineral and prevent bone resorption by influencing the apoptosis of osteoclasts. Localized delivery using biodegradable materials, such as polylactic acid (PLA) and hydroxyapatite (HAp), which are ideal in this approach, have been used in this study to investigate the dissolution of clodronate (non-nitrogen-containing bisphosphonate) in a new release system. The effects of coral structure-derived HAp and the release kinetics of the composites were evaluated. The release kinetics of clodronate from PLA–BP and PLA–HAp–BP systems seemed to follow the power law model described by Korsmeyer–Peppas. Drug release was quantified by 31P-NMR with detection and quantification limits of 9.2 and 30.7 mM, respectively. The results suggest that these biocomposite systems could be tuned to release clodronate for both relatively short and prolonged period of time. In addition to drug delivery, the degradation of HAp supplies both Ca2+ and phosphate ions that can help in bone mineralization. Copyright © 2015 John Wiley & Sons, Ltd.	en_US
dc.relation.ispartof	Journal of Tissue Engineering and Regenerative Medicine	en_US
dc.relation.isbasedon	10.1002/term.2066	en_US
dc.subject.classification	Biomedical Engineering	en_US
dc.subject.mesh	Durapatite	en_US
dc.subject.mesh	Clodronic Acid	en_US
dc.subject.mesh	Polyesters	en_US
dc.subject.mesh	Delayed-Action Preparations	en_US
dc.subject.mesh	Porosity	en_US
dc.title	Development and dissolution studies of bisphosphonate (clodronate)-containing hydroxyapatite–polylactic acid biocomposites for slow drug delivery	en_US
dc.type	Journal Article
utslib.citation.volume	6	en_US
utslib.citation.volume	11	en_US
utslib.for	0903 Biomedical Engineering	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	1116 Medical Physiology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CCET - Centre for Clean Energy Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	closed_access
pubs.issue	6	en_US
pubs.publication-status	Published	en_US
pubs.volume	11	en_US

Abstract:

Copyright © 2015 John Wiley & Sons, Ltd. An increase in clinical demand on the controlled release of bisphosphonates (BPs) due to complications associated with systemic administration, has been the current driving force on the development of BP drug-release systems. Bisphosphonates have the ability to bind to divalent metal ions, such as Ca2+, in bone mineral and prevent bone resorption by influencing the apoptosis of osteoclasts. Localized delivery using biodegradable materials, such as polylactic acid (PLA) and hydroxyapatite (HAp), which are ideal in this approach, have been used in this study to investigate the dissolution of clodronate (non-nitrogen-containing bisphosphonate) in a new release system. The effects of coral structure-derived HAp and the release kinetics of the composites were evaluated. The release kinetics of clodronate from PLA–BP and PLA–HAp–BP systems seemed to follow the power law model described by Korsmeyer–Peppas. Drug release was quantified by 31P-NMR with detection and quantification limits of 9.2 and 30.7 mM, respectively. The results suggest that these biocomposite systems could be tuned to release clodronate for both relatively short and prolonged period of time. In addition to drug delivery, the degradation of HAp supplies both Ca2+ and phosphate ions that can help in bone mineralization. Copyright © 2015 John Wiley & Sons, Ltd.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/95771